Immunome (IMNM) Non-Current Debt (2020 - 2021)

Immunome's (IMNM) quarterly Non-Current Debt came in at $134000.0 in Q1 2021, little changed on a QoQ basis from $134000.0 in Q4 2020.

Immunome (IMNM) Non-Current Debt (2020 - 2021) Analysis & Trends

Immunome (IMNM) has 2 years of Non-Current Debt data on file, last reported at $134000.0 in Q1 2021.

Quarterly Non-Current Debt changed N/A year-over-year to $134000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $134000.0 (changed N/A YoY) and the FY2020 annual result came in at $134000.0, changed N/A from the prior year.
Non-Current Debt steadied at $134000.0 in Q1 2021, from $134000.0 in the prior quarter.
In the past five years, Non-Current Debt ranged from a high of $195000.0 in Q3 2020 to a low of $134000.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	882.16 Mn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	8.96 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Immunome	3.09 Bn	2.57 Bn	-	-

Download Data